Mizuho Lowers Leap Therapeutics (NASDAQ:LPTX) Price Target to $2.00

Leap Therapeutics (NASDAQ:LPTX – Get Rating) had its target price cut by stock analysts at Mizuho from $3.00 to $2.00 in a note issued to investors on Friday, The Fly reports. The brokerage currently has a “buy” rating on the stock. Mizuho’s price objective would indicate a potential upside of 449.15% from the stock’s previous close.

Several other equities research analysts also recently weighed in on the company. HC Wainwright cut their price target on Leap Therapeutics from $4.00 to $2.50 and set a “buy” rating on the stock in a report on Wednesday, January 18th. Robert W. Baird cut their price target on Leap Therapeutics to $4.00 in a report on Monday, November 21st. Finally, Piper Sandler cut their price target on Leap Therapeutics from $4.00 to $3.00 in a report on Tuesday, January 17th.

Leap Therapeutics Price Performance

Shares of NASDAQ LPTX opened at $0.36 on Friday. The stock’s 50-day moving average is $0.57 and its two-hundred day moving average is $0.71. Leap Therapeutics has a 1-year low of $0.35 and a 1-year high of $1.95. The company has a market cap of $36.06 million, a price-to-earnings ratio of -0.77 and a beta of 0.75.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in LPTX. Integrated Wealth Concepts LLC acquired a new position in shares of Leap Therapeutics during the 1st quarter worth about $26,000. Virtu Financial LLC boosted its position in shares of Leap Therapeutics by 44.2% during the 2nd quarter. Virtu Financial LLC now owns 28,865 shares of the company’s stock worth $33,000 after acquiring an additional 8,852 shares in the last quarter. Annandale Capital LLC acquired a new position in shares of Leap Therapeutics during the 3rd quarter worth about $35,000. Private Advisor Group LLC boosted its position in shares of Leap Therapeutics by 104.5% during the 1st quarter. Private Advisor Group LLC now owns 22,500 shares of the company’s stock worth $39,000 after acquiring an additional 11,500 shares in the last quarter. Finally, Two Sigma Investments LP acquired a new position in shares of Leap Therapeutics during the 4th quarter worth about $44,000. 37.44% of the stock is owned by institutional investors and hedge funds.

About Leap Therapeutics

(Get Rating)

Leap Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. Its clinical stage programs are DKN-01, which is a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1 and TRX518, which is a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor, or GITR.